Develops therapies for rare diseases and conditions, focusing on neurology and pediatric endocrinology.
Soleno Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, dedicated to advancing innovative therapies aimed at addressing rare diseases. At the forefront of its portfolio is Diazoxide Choline Controlled-Release, a once-daily oral tablet designed specifically for treating Prader-Willi Syndrome. This lead candidate is currently undergoing rigorous evaluation in a Phase III clinical development program, highlighting Soleno Therapeutics' commitment to providing potential breakthrough treatments for patients facing challenging medical conditions.
Founded in 1999 and headquartered in Redwood City, California, Soleno Therapeutics, Inc. was previously known as Capnia, Inc. before rebranding in May 2017. The company has strategically positioned itself within the biopharmaceutical landscape, focusing on rare diseases where there is significant unmet medical need. Soleno Therapeutics leverages its scientific expertise and research capabilities to drive advancements in therapeutic solutions, aiming to improve the quality of life for patients and families affected by these disorders.
In addition to its pioneering work in Prader-Willi Syndrome, Soleno Therapeutics continues to explore and expand its pipeline to address other rare diseases. With a steadfast commitment to clinical excellence and patient-centric innovation, the company remains dedicated to transforming the treatment landscape and bringing hope to individuals with underserved medical conditions worldwide.